The FDA on Monday approved Biogen and Samsung Bioepis’ Byooviz, a biosimilar to Roche’s blockbuster eye drug Lucentis. The approval marks Samsung Bioepis’ fifth biosimilar win. For the treatment of age-related macular degeneration, Lucentis holds covered or better status for 49% of all insured lives under the pharmacy benefit. It is not covered for 30.6% of lives.
SOURCE: MMIT Analytics, as of 9/22/21